Disparities in Receipt of Medications for Opioid Use Disorder Before and During the COVID-19 Pandemic in the US Veterans Health Administration
- PMID: 39569566
- DOI: 10.1177/29767342241293334
Disparities in Receipt of Medications for Opioid Use Disorder Before and During the COVID-19 Pandemic in the US Veterans Health Administration
Abstract
Background: Populations disproportionately impacted by the opioid epidemic are less likely to receive medications for opioid use disorder (MOUD; OUD). The COVID-19 pandemic exacerbated these disparities. We performed an ecological survey of subpopulations to compare differences in MOUD receipt among Veterans with OUD before versus during the pandemic.
Methods: Using 2 cross-sections of 2 time periods of national Veterans Health Administration electronic health record data, we calculated proportions of Veterans with any MOUD receipt by demographics, Elixhauser comorbidity index, and natural language processing (NLP)-derived substance use and social determinants of health in each time period. We evaluated differences in MOUD receipt before and during the pandemic by patient characteristics using Chi-square and Cohen's h for effect size.
Results: Among 62 195 patients with OUD before the pandemic, the proportion prescribed MOUD increased from 46.5% before to 47.5% (P = .0003) during the pandemic. Statistically significant increased receipt of MOUD was observed for patients who were ≥55 years, men, White, with Elixhauser comorbidity indices of 2 and ≥5, and with NLP-derived indicators of substance use. There was a decrease that did not achieve statistical significance in MOUD receipt from before to during the pandemic for patients who were women, Black, Latinx, and food insecure.
Conclusions: The proportions of patients with OUD prescribed MOUD increased from before to during the pandemic. However, Veterans who were women, Black, Latinx, and food insecure did not experience these increases. These patients may benefit from interventions such as targeted outreach efforts to improve MOUD engagement to reduce OUD harms.
Keywords: COVID-19 pandemic; medications for opioid use disorder; opioid-related disorders; social determinants of health.
Conflict of interest statement
Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Similar articles
-
Initiation and Receipt of Medication for Opioid Use Disorder Among Adolescents and Young Adults in 4 State Medicaid Programs in 2018: Improving Medicaid Quality Metrics.Subst Use Addctn J. 2024 Jul;45(3):434-445. doi: 10.1177/29767342241227791. Epub 2024 Jan 31. Subst Use Addctn J. 2024. PMID: 38294428
-
Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder by Race and Ethnicity and Insurance Type.JAMA Netw Open. 2025 Jun 2;8(6):e2518493. doi: 10.1001/jamanetworkopen.2025.18493. JAMA Netw Open. 2025. PMID: 40569592 Free PMC article.
-
The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review.Addict Sci Clin Pract. 2021 Oct 11;16(1):62. doi: 10.1186/s13722-021-00266-2. Addict Sci Clin Pract. 2021. PMID: 34635170 Free PMC article.
-
Changes in Food Insecurity Among US Adults With Low Income During the COVID-19 Pandemic.JAMA Netw Open. 2025 Feb 3;8(2):e2462277. doi: 10.1001/jamanetworkopen.2024.62277. JAMA Netw Open. 2025. PMID: 40019759 Free PMC article.
-
Opioid treatment programs, telemedicine and COVID-19: A scoping review.Subst Abus. 2022;43(1):539-546. doi: 10.1080/08897077.2021.1967836. Epub 2021 Sep 14. Subst Abus. 2022. PMID: 34520702 Free PMC article.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical